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Meriem Manaı̈a,b,*, Henriët van Middendorpa,b, Dieuwke S. Veldhuijzena,b, Tom W.J. Huizingac,
Andrea W.M. Eversa,b,d
Abstract
Nocebo effects, such as side effects due to negative expectations regarding the pain treatment, are a concern for health care
providers and come with significant costs. This narrative review focuses on underlying mechanisms and possible factors that
contribute to the susceptibility to the nocebo effect on pain and related outcomes and suggests strategies that can prevent,
minimize, or extinguish nocebo effects in clinical settings. Nocebo effects are the result of psychological (eg, conditioning,
verbal suggestions, and observational learning) and neurobiological (eg, cholecystokinin and dopamine regulation)
mechanisms. Evidence from clinical and experimental studies lead to various recommendations and strategies to alter the
nocebo effect in order to optimize pain treatments, such as providing patients with enhanced information, optimizing
patient–physician communication and relationships, and offering psychoeducation on coping skills in order to manage patient
expectations. The current literature from both clinical and experimental studies provides a better understanding of the nocebo
effect and possible factors that modulate its strength on treatment outcomes. This allows for the development of evidence-
based strategies aimed at the prevention, minimization, and treatment of the nocebo effect in pain conditions and possible
other somatic disorders.
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1. Introduction
In clinical trials and practice of pain treatments, there is a large
interindividual variability in treatment outcome between patients.5
One important factor influencing the interindividual variability is
the role of expectations, which can optimize or add to analgesic
treatment outcomes in case of positive expectations (so-called
placebo effects) or worsen pain or cause for inadequate pain relief
in case of negative expectations (so-called nocebo).26,29,97,123 A
growing body of literature is focusing on how the positive effects
that can be reached by using placebo effects can be optimized for
use in clinical practice.2,39,58,102,103 Much less attention has been
paid to the question on how to prevent, minimize, or extinguish
negative expectations by means of the nocebo effect in clinical
practice. However, since negative or nocebo expectations (eg,
“The pain will worsen,” “I always react hypersensitive to
medication”) have shown even stronger effects than positive or
placebo expectations, possibly due to the evolutionary de-
termined bias for negative threatening information, looking into
ways to diminish the nocebo effect is highly relevant.8
The nocebo effect is an adverse effect to a treatment that cannot
be ascribed to a specific treatment mechanism.105 Instead, this
effect is caused by the expectations that a person has about the
effects of the treatment.5,11,63 Examples of the nocebo effect
include the reporting of side effects in the placebo condition of
randomized controlled trials,34,98,109 the experience of a pain
increase in response to the doctor saying that a painful procedure
will take place,14,25,30,127 or becomingnauseouswhenentering the
hospital where one receives chemotherapy.5,22,115
Because nocebo expectations lead to adverse effects, such as
negative treatment outcomes, they can contribute to significant
costs of (chronic) clinical conditions in the form of decreased
quality of life, treatment nonadherence, financial costs for health
services, and societal costs.126 For this reason, it is highly relevant
to prevent, minimize, or extinguish nocebo effects in (chronic)
pain conditions. Therefore, the current article will provide
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a narrative review on nocebo applications in pain and related
conditions in both experimental and clinical settings, to identify
factors that may cause increased susceptibility to the nocebo
effect and to formulate concrete and to specific situations tailored
recommendations on how to prevent, minimize, or extinguish the
nocebo effect in clinical practice.
2. Learning mechanisms of nocebo effects
Expectations play a pivotal role in placebo and nocebo effects for
pain and related conditions.49,64,82 Learning theories explain that
expectations, in particular response expectancies, can be
acquired in various ways, including conditioning, instructional
learning through verbal suggestions regarding treatment effects,
and observational learning,6,7,10,78,82 see also Figure 1. These
mechanisms do not only exert influence on behavior, but also on
nonvolitional physiological responses.27,89 In conditioning, new
associations are formed by repeatedly pairing 2 stimuli, whereby
specific conscious or automatic expectations (eg, nausea due to
chemotherapy3) or latent responses (eg, conditioned immune
responses39) are induced. Research in both experimental and
clinical settings has shown that these repeated pairings between
a neutral stimulus and a physiological outcome can result in
conditioned nocebo effects.3,5–7,15,34,98,99,109 Because of the
conditioning process whereby associations are formed between
a treatment and its outcome and possible side effects, patients
who have had previous negative experience with a treatment are
more prone to experience nocebo effects when starting a new
treatment. Previous experiencewith side effectsmay also result in
the attribution of common maladies to medication side
effects.5,28,31,32 For instance, previous experience with chemo-
therapy will cause for nocebo nausea in a substantial number of
patients.1,3,83,129 In addition, infants receiving repeated heal
lances in the first 24 to 36 hours of life to monitor blood glucose
levels showedmore intense pain responses than infants receiving
only one painful procedure. Furthermore, the skin cleaning
procedure that infants underwent for each heal lance resulted
in anticipatory pain behaviors, indicating that the cleaning
procedure became a conditioned stimulus.114 These studies
suggest that nocebo effects can be induced by environmental
stimuli associated with the treatment, such as the sight of
a familiar health care worker, the sounds and smells of the
treatment context, the sight of the color and shape of the
medication itself, or a cleaning procedure.5,114 Conditioning
subsequently reinforces and generalizes the side effects that
patients experience by a process of sensitization and can be
strengthened even further with the number of conditioning
sessions.31
In addition to learned associations, instructional learning,
such as verbal information about negative treatment out-
comes, can influence somatosensory perception and can
result in symptom aggravation.14,32 This is evident in
patient–physician communication whereby the information
on the risks of a possible treatment can induce negative
expectations and treatment anxiety, resulting in nocebo
effects.5,14,25,30,129 For example, in a trial studying the effects
of pharmacological treatments of unstable angina, patients
who were informed about possible gastrointestinal side effects
of the treatments withdrew 6 times more often due to minor
gastrointestinal complaints than patients who did not receive
this information.84 Nocebo effects have also been induced in
pain and other conditions by giving negative verbal sugges-
tions about the expected outcome after a clinical treatment or
experimental manipulation.6,14,15,25,30,118
Robust empirical evidence shows that nocebo effects can be
caused by conditioning, verbal suggestion, or a combination of
the two.14,28,32,37,90,105,126 Although placebo research indicates
that learned associations due to previous experience with
a treatment (conditioning) can cause stronger placebo responses
than verbal suggestions and that the combination of a condition-
ing procedure with verbal suggestions results in additive placebo
effects,95 this is not necessarily the case for nocebo effects.24,32
For instance, one study in line with the placebo literature showed
that nocebo itch was only induced in a group that underwent
a conditioning procedure in combination with verbal suggestions
about the intensity of the itch stimuli compared with groups that
underwent these procedures separately or a control group.6 By
contrast, another study found no differences between either
conditioned pain or pain induced by verbal suggestions,
suggesting that conditioning is less dominant in evoking nocebo
than placebo responses.32 However, in the latter case, this could
also be due to the type of stimulus applied in this study, namely
electric shock. Here, the stimulus can easily be interpreted as
dangerous, and therefore, it does not necessarily need previous
experience to perceive the stimulus as a potential painful threat.32
Finally, strong nocebo effects can also be evoked through
a third learning mechanism, observational learning, which can
even be more robust than verbal suggestion about possible
negative effects.10,48,88,123 It has, for example, been shown that
watching a person with intensified pain after the application of an
ointment led to larger increases in pain ratings in response to
a subsequent pain stimulus than verbal suggestions that the
ointment increased pain intensity.123 The finding that observa-
tional learning can elicit nocebo effects suggests that first-hand
experience through conditioning or verbal suggestion are not the
only key factors in the nocebo phenomenon, but that social
learning and interaction play essential roles as well.10,48,88
These studies indicate that several psychological learning
mechanisms are at play in the nocebo effect and may provide
different avenues for the development of possible treatments that
target nocebo effects. However, the combination and interaction
of the various mechanisms need further investigation to gain
insight in how to be optimally used.
3. Neurobiological mechanisms of the
nocebo effect
Neuroimaging studies have provided evidence that the
anticipation of pain, due to negative pain expectations,
activates several brain regions involved in processing noci-
ceptive stimuli. These include the prefrontal cortex, the
thalamus, the secondary somatosensory cortex, the anterior
cingulate cortex, the parietal operculum, and the insular
cortex.18,37,54,61,67,74,92–94,101,104,105 Furthermore, the
expected intensity of a noxious stimulus increases activation
in the thalamus, the prefrontal cortex, the anterior cingulate
cortex, the head of the caudate, the cerebellum, and the
contralateral nucleus cuneiformis.61,67
Neurochemical pain research indicates that anticipatory anxiety,
also associated with negative expectations, activates at least 2
independent pathways, namely the hypothalamus–pituitary–adrenal
(HPA) axis, which controls reactions to stress,68 and the cholecys-
tokinin (CCK-ergic) system, which is involved in the regulation of
nociception, anxiety, and memory.37 In this nocebo pain model, the
HPA axis is activated by nocebo suggestions and results in
anticipatory anxiety. This has been shown in various studies that
saw an increase in both cortisol and adrenocorticotropic hormone
after verbally induced nocebo hyperalgesia.13,56 After the
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administration of diazepam, a benzodiazepine anxiolytic drug, both
HPA activation and pain perception were reduced, confirming the
role of (anticipatory) anxiety in nocebo hyperalgesia.13 In turn, this
anticipatory anxiety activates the CCKergic system, which
activates descending pronociceptive pathways from the peri-
aqueductal gray and mediates anxiety-induced hyperalge-
sia.13,65,75 Indeed, infusion of the CCK-blocking drug
proglumide reverses the nocebo effect.12,13 In addition, in-
creasing research focuses on the interaction between CCK and
opioids and dopamine (DA) because it has been found that CCK
acts as a neuromodulator of pain, whereas opioids and DA have
pain-relieving properties.9,107 Similarly, CCK can be activated by
verbal suggestions of pain increase (nocebo), whereas endog-
enous m-opioid neurotransmitters and DA can be activated by
suggestions of pain decrease (placebo).107 Finally, because CCK
antagonizes opioid effects,9 the CCK-induced nocebo effects
deactivate opioid and DA release.107 These findings open up new
avenues of pharmacotherapeutic strategies for pain treatment
when anxiety is involved. Namely, CCK-blocking pharmacother-
apeutics could be applied to limit anticipatory anxiety, with or
without combining these with positive verbal suggestions, to
activate neurochemical placebo responses in the form of
m-opioid and DA.
In summary, several neurobiological and neurochemical
trajectories are suggested to work independently and interact
to produce nocebo effects. However, further research is needed
to gain a better understanding of both their separate and their
overlapping roles for possible additive and interactive effects.
4. Susceptibility to the nocebo effect
The nocebo effect is formed by multifaceted factors that relate to
the individual and interact with the environmental context of
clinical and laboratory settings.5 Examples of individual charac-
teristics that can influence the magnitude and the prevalence of
the nocebo effect include genotype variations, age and sex,
personality characteristics, and psychological distress.
4.1. Genetics
Research indicates that genetic variations can influence the
nocebo effect.21 An example is the rs4680 single-nucleotide
polymorphism, which is a well-studied gene for catecholamines-
O-methyltransferase (COMT) that metabolizes DA and other
catecholamines.69 This gene codes a valine (val) amino acid to
a methionine (met) at codon 158 (val158met). Homozygotes for
the less-active rs4680 met allele (met/met) metabolize DA at
a lower rate and showed a larger placebo response than
homozygotes for the highly active val allele (val/val). The latter
population not only shows smaller placebo responses, but also
Figure 1. Learning mechanisms of the nocebo effect.
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reports more nocebo symptoms.51,69,128 Coincidentally, re-
search found that, compared with the other genotypes (hetero-
zygotes andmet/met homozygous carriers), homozygote carriers
of the val158 have a higher disposition to detect somatic and
visceral sensations and experience these sensations as strong,
unpleasant, and harmful. Furthermore, people with val/val
genotypes believe more strongly that medication will harm them,
are more sensitive to their effects, and are more concerned about
possible side effects of medication.128 Because evidence
suggests that genotype variations involved in DA modulation
may influence the nocebo effect, other polymorphisms may exert
their influence on this reward pathway as well. For instance, the
rs6323 single-nucleotide polymorphism for monoamine oxidase
A (MOA-A) not only metabolizes monoamines, but also seroto-
nin.80 Previous research has shown that increased serotonin
levels stimulate the placebo response but counteract the nocebo
effect in patients with Parkinson disease.15 Although these
studies provide knowledge of the possible moderators of the
nocebo effect, it should be considered that our knowledge in this
area is still limited.
4.2. Age and sex
Studies that focused on the role of age have not yet shown
a significant role of age for the susceptibility to the nocebo
effect.34,45,47,73,131 In addition, most research on nocebo effects
shows that sex does not significantly contribute to the nocebo
effect.126 However, some studies did find that women are more
susceptible for nocebo effects than men.17,72,91,112,113 For
instance, a study66 investigating the effect of sex on conditioning
or verbal suggestions in healthy adults found that women showed
a larger nocebo effect after induced nausea than men.
Furthermore, women were more affected by conditioning than
by verbal suggestions, whereas men responded stronger to
verbal suggestions. This could indicate that finding sex differ-
ences in the susceptibility to the nocebo effect is dependent on
the way the nocebo effect is induced. These potential sex
differences might also be mediated by cognitive variables. For
instance, research suggests that women may have more stable
negative outcome expectancies because correlations indicate
that women tend to worry more than men71,77,100,110 and are
possibly more oriented towards problems.100 Future research is
needed to gain knowledge on whether the interaction between
sex and cognitions may have an influence on nocebo effects in
acute situations such as in an experimental setting or in
clinical practice during physician consultations. In addition,
although the influence of age and sex on nocebo effects in
various clinical populations with diverse symptomologies has
been studied,126 few studies are available that studied their
influence on nocebo pain specifically. Therefore, further
exploration of these influences on nocebo effects for pain
would add significantly to the literature.
4.3. Types of pain
Nocebo pain has been well studied in instances of acute
nociceptive pain, for example, in experimental settings whereby
a noxious stimulus is applied or in patient populations suffering
from postoperative pain.120 Furthermore, randomized controlled
trials investigating active drugs compared with a placebo arm
have expanded the knowledge on nocebo responding to placebo
treatment in, for example, neuropathic pain.43 However, because
studies that involve nocebo effects in randomized controlled
clinical trials usually compare an active drug with a placebo arm,
but not to a no-treatment control arm, the natural history of pain is
not controlled for. This makes it difficult to infer whether nocebo
effects are actually due to nocebo components or other factors,
such as regression to the mean. Furthermore, nocebo pain may
differ depending on the setting, being either experimental or
clinical. However, no strong conclusions can be drawn regarding
this potential difference because of the heterogeneity in
populations and selection of outcome measures (eg, pain, itch,
or nausea). Few studies120 have attempted to elucidate what
roles different types of pain (eg, nociceptive, neuropathic, acute,
or chronic pain) play in the nocebo effect, and more research is
needed to gain conclusive knowledge on the potential separate
and overlapping underlying mechanisms of different types of pain
in nocebo responding or the setting in which nocebo pain takes
place (experimental vs clinical).
4.4. Type of medication
Not much research has investigated whether the type of
medication received by the patient can significantly contribute
to the nocebo effect. A recent meta-analysis121 indicated that
opioid trials are correlated with higher placebo responses than
nonopioid pain medication. This may be due to several factors.
First, opioids are established as potent analgesics, and patients
may therefore have pre-established expectations on their
efficacy. Second, research121 indicates that opioid trials are also
accompanied by a higher number of face-to-face visits, which
may have an influence on instructional learning, because there is
a higher chance of verbal instructions on the opioids’ efficacy
being repeated, thereby strengthening expectations. Although
these findings indicate that the type of drug associated with
nocebo effects may have an influence on nocebo responding,
more research is needed.
4.5. Personality characteristics
Althoughmore research is needed to clarify the role of personality
on nocebo effects, certain personality traits have been linked to
the susceptibility to the nocebo effect. For instance, although
optimists seem to be more responsive to the placebo effect,33,46
pessimists may be more vulnerable for nocebo effects.33,45 In
addition, individuals with type A personalities, who can be
described as more aggressive, competitive, and impatient,16,36
aremore likely to report side effects than typeB individuals,36 who
may be less aggressive andmore easy going.16,36 Lower levels of
extraversion, which can be construed as being more outgoing
and talkative,42 have also been indicated as a possible contrib-
uting factor in the nocebo effect.6 Anxiety, psychological
suggestibility, and worrying seem to significantly correlate with
nocebo effects.6,33,106,122 Patients with rheumatoid arthritis were
found to be at greater risk of developing treatment side effects if
they worried more about their medication intake, especially when
starting a new treatment.85,86 Patients who worry more about
developing negative side effects may bemore attuned to adverse
symptoms and may interpret any sensation, whether new or
preexisting, to their medication intake, while at the same time
ignoring the positive effects of a treatment.5 Mixed results have
also been found for imaginative involvement, which can be
described as the ability to experience suggestions imaginatively,
where one study found that higher levels of imagination were
related to stronger nocebo effects on itch,106 whereas another
study did not find any significant correlations for imaginative
involvement in nocebo itch induced by verbal suggestions and
pain responses.118
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Certain personality traits may predispose individuals to the
nocebo effect and insight into their contribution to nocebo
responding allowing for the tailoring of evidence-based strate-
gies to minimize or manage the nocebo effect in clinical settings
to specific subgroups of patients most vulnerable to nocebo
effects. However, more empirical investigation is needed
because research in this area is not yet comprehensive and
conclusive.
4.6. Psychological distress
Patients with symptoms of depression seem to be more prone to
developing nocebo side effects. It has been theorized that these
patients are more focused on somatic sensations, are more
inclined to expect negative outcomes, andmay even feel that they
deserve negative outcomes.5 Furthermore, patients with con-
ditions such as depression or anxiety have a tendency to
somaticize, which has been shown to result in increased reports
of side effects.5,76 For example, patients with rheumatoid arthritis
who had higher baseline reports of somatization and a tendency
to exaggerate negative somatic sensations were more likely to
develop nocebo effects.116 Negative side effects reported by
highly anxious patients tend to be similar to symptoms of anxiety
itself, such as tachycardia, dyspnea, and sweating.91 Thus,
factors related to psychological distress, such as symptoms of
depression and anxiety, may contribute or aggravate suscepti-
bility to the nocebo effect by emphasizing the focus on negative
somatic symptoms.
The influence on the nocebo effect of these person-related
factors and the manner in which they interact with the social and
environmental context suggests that these multifaceted in-
dividual factors may be deployed in the manipulation of nocebo
effects.
5. Challenges and opportunities: recommendations
to prevent, minimize, and extinguish the nocebo
effect in clinical practice
Because the occurrence of the nocebo effect has been established
in awide variety of clinical populations,5,14,25,28,65,90,105 it is essential
to develop strategies that can prevent, minimize, or extinguish its
adverse effects. Several factors contribute to the strength of the
nocebo effect, such as patient–physician relationship and physician
communication style.25,30 These contributing factors can be used
as a basis on which recommendations can be formulated to pre-
vent, minimize, or extinguish the nocebo effect. For example,
screening instruments could be implemented to identify person-
alities that may have an increased risk for nocebo responding.
Basedon the outcomeof the screening, pharmacological treatment
could be supplemented with psychological strategies that help
manage physical, psychological, and social functioning. Based on
the current literature,25,28,30,40,65,125 evidence-based ethical rec-
ommendations can be developed to optimally treat the nocebo
effect in clinical practice, see also Table 1.
5.1. Enhanced treatment information
Because verbal and nonverbal communication can induce
negative treatment expectations that may result in nocebo
effects,5,52 patient–clinician communication is of utmost impor-
tance. Even when negative associations are formed based on
one encounter with negative information in the form of verbal
suggestions or informational leaflets, without the process
of conditioning, a once established nocebo effect can be long-
lasting.14,25,65,101 Often in clinical practice, the limited time that
clinicians have during appointments with patients leads to a shift
in the priority to giving patients very concise information regarding
a new treatment, with a focus on possible side effects of a treat-
ment as opposed to emphasizing the potential positive effects of
a treatment. The clinical environment can therefore un-
intentionally induce nocebo effects.65,129 Providing enhanced
information about the nocebo effect itself and the prescribed
treatment could prevent the induction of nocebo effects.40,119
Giving enhanced treatment information by a trained professional
in addition to standard clinical information may lead to higher
satisfaction and knowledge about the illness and its treatment.53
A better understanding of the prescribed treatment may exert
a positive influence on patients who show concerns about
medication intake andmedication dependence.55 As these types
of worries may exacerbate the nocebo effect, providing extended
treatment information may be a strategy in preventing or mini-
mizing nocebo responding.
5.2. Optimization of patient–clinician communication
Verbal suggestions are a powerful strategy to enhance negative
expectations and can induce or strengthen nocebo effects.
Therefore, the information that physicians provide their patients
on the treatment and its possible side effects could induce strong
nocebo effects. For this reason, treatment information can be
conveyed in such a way that positive treatment effects are
emphasized, while avoiding the overemphasis on treatment side
effects.30,65 In this positive framing method, an ethical balance
should be maintained to minimize clinician-induced nocebo
effects through verbal suggestions on possible treatment side
effects, while simultaneously respecting patient autonomy,
because clinicians have an obligation to thoroughly inform their
patients on important treatment information.38 Wells et al.127
therefore suggest that clinicians apply contextualized informed
consent, which involves giving tailored information about
medication side effects while considering various components,
such as the person, the disease under treatment, and the
possible side effects of the treatment. However, because
physicians have an ethical duty to provide full treatment
disclosure, Colloca23 suggests informing patients on the nocebo
phenomenon and asks if patients would prefer to not be informed
about possible side effects of a treatment and essentially provide
authorized concealment. If the patient does prefer to receive full
Table 1
Strategies to prevent, minimize, and extinguish the nocebo effect
in clinical practice.
Provide enhanced treatment information
Provide information on the nocebo effect itself
Provide extensive and comprehensive treatment information (eg, information on
the treatment itself by a trained professional in addition to standard clinical
information).
Optimize patient–clinician communication
Emphasize positive treatment outcomes
Authorized concealment in providing side effect information
Create trusting and empathetic consultation environment
Provide education on communication for health care providers
Screen patients on risk for nocebo effects and offer tailored treatment
Use screening tools to identify patients at risk for nocebo effects (eg, fear of side
effects, insufficient knowledge of condition and treatment)
Implement individualized interventions to reduce nocebo effects based on
patients’ needs (eg, counterconditioning of negative treatment experiences)
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disclosure, a physician may ask the patient to contact her/him if
any new or unusual symptoms should arise instead of listing the
nonspecific side effects of a treatment. In addition, talking
about the chances of not experiencing side effects is preferred
over giving information on the chances of experiencing possible
side effects.126 An example is provided by a study87 in which
unimmunized patients with chronic respiratory or cardiac
disease were either informed about the percentage of
recipients of the influenza vaccine who remain free of influenza
and do not experience vaccine side effects, or received
information on the percentage who do acquire influenza and
suffer from vaccine side effects. The group that received
positively framed information reported fewer side effects and
less work absenteeism.88
Research suggests that health care providers could receive
education on how nocebo effects can influence clinical outcomes
and how to convey information in such a way to prevent or
minimize nocebo responding from occurring.40 In turn, physi-
cians could convey information on the nocebo effect to their
patients and either withhold negative treatment information
(authorized concealment) or incorporate a positive framing style
of communication.23,28,65 Other evidence-based recommenda-
tions to improve patient–clinician communication include to
identify patient expectations and possible fears, and to evaluate
the patient’s understanding of the diagnosis and suggested
treatment.59 This could be especially important in patient pop-
ulations that are highly susceptible to the nocebo effect,108 such
as people with negative previous treatment experience or people
who worry more.126 Optimizing the communication style in clini-
cal settings could be an important approach in preventing or
minimizing nocebo effects.
5.3. Optimization of patient–clinician relationship
Not only negative information itself could lead to nocebo effects
but also nonverbal communication and communication style,
such as keeping a medical consult formal and not providing
a trusting and empathetic environment,5,35,52,59 as research has
shown that the manner in which a physician is perceived can
influence the effectiveness of a treatment.59,60,111 Clinicians who
convey a sense of warmth, friendliness, and reassurance obtain
more effective treatment effects than clinicians who keep their
consults formal without any form of reassurance. An effective
patient–clinician relationship involves mutual trust, empathy, re-
spect, genuineness, acceptance, and warmth.35,59 Because
negative associations between the clinical context and a treat-
ment could elicit strong nocebo effects, it is preferred to create an
environment that is associated with positive expectations rather
than feelings of fear and uncertainty. This is especially important
for health care workers who have direct patient contact as
merely seeing them could elicit nocebo effects.5,35,59 Therefore,
physician educational strategies that focus on communication
skills that promote trust, mutual understanding, adherence,
social support, and self-efficacy could foster positive expect-
ations about the suggested treatment outcome and minimize or
even prevent nocebo effects.40,111
5.4. Managing patients’ treatment expectations
According to Leventhal’s Common Sense Model of Self-
Regulation,70 patients develop cognitive lay representations of
their illness and the treatment thereof. These representations
guide coping strategies to manage health threats. Because of the
heterogeneity in coping strategies (eg, avoidance, cognitive
reappraisal, emotion venting, and seeking social support50) and
their efficacy, individuals hold different expectations on being able
to control their own health, which predicts stress.79 Therefore, it
seems useful to offer patients the strategies to manage their
expectations regarding treatment.70 This strategy was demon-
strated in a case study125 whereby 2 patients were offered a side
effect prevention training including psychoeducation about the
disease and the treatment, adopted to patients’ previous
knowledge, promotion of doctor–patient communication, in-
formation about the nocebo effect, and conditioning processes
involving the formation of associations between the medication
and positive sensory experiences (eg, a beautiful song), and
pleasant emotions and expectations by means of imagination
exercises. Results indicated that a personalized approach im-
proved treatment expectations and quality of life and reduced
treatment side effects. For instance, greater self-efficacy was
achieved by means of making coping strategies more concrete
for the patient who had considerable previous knowledge and
medical understanding. Conversely, the patients with less pre-
vious knowledge and who suffered from progressive anxiety
benefitted more from psychoeducation aimed at the illness and
its treatment. Such an individualized approach has been shown
to be beneficial in previous research, in which individuals who
regularly used avoidance as a coping strategy benefitted most
from short and basic information, while anxious patients
benefitted most from detailed information on positive treatment
effects.81,130 Therefore, a possible avenue that aims at nocebo
prevention could focus on optimizing coping strategies, based on
the patient’s needs, which can be identified by means of efficient,
reliable, and valid screening instruments. These instruments may
focus on risk factors such as fear of side effects and negative
treatment expectancies.81,125,130
5.5. Selection of and tailoring treatment to patients at risk
Many pharmacological treatments come with considerable side
effects, whether induced by the active medication or by negative
treatment expectations. As these side effects have a negative
impact on quality of life and could lead to treatment non-
adherence, it is imperative to develop methods to prevent
possible side effects from occurring.5,28,65 Therefore, strategies
could be implemented that identify patients at risk and offer these
patients enhanced side effect information in a manner that
prevents the development of negative treatment expecta-
tions.41,125 Reliable and valid (web-based) screening instruments
could be incorporated to identify patients at risk for nocebo side
effects. These include personality traits,45,106,122 psychological
distress,5,76 and negative previous experience with pharmaco-
logical treatments.5,28,31,32 Based on screening outcomes,
(guided) tailored psychological trainings could be offered, which
may include both generic components as well as treatment-
specific side effect information that optimizes positive treatment
expectations.41 An example of a possible intervention was
developed for breast cancer patients undergoing endocrine
therapy.124 The intervention included giving information on the
treatment itself and the nocebo effect, guided imagination
exercises that focused on control and positive expectations,
optimizing coping skills by teaching problem-solving skills related
to the most common side effects of endocrine therapy, reducing
specific concerns by preparing cognitive and behavioral strate-
gies, and optimizing coping skills regarding treatment expect-
ations. Such tailored interventions may enhance positive
treatment expectations, prevent or reduce fear of side effects,
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and provide effective coping strategies if (nocebo) side effects
should occur.
5.6. Reversing the nocebo effect
Induction of nocebo effects can not always be prevented.
Therefore, it is useful to be able to reverse nocebo effects once
they are established. Several strategies exist that could be used
to reverse acquired nocebo effects. One such strategy is
extinction. In extinction, a conditioned stimulus that induces
a nocebo effect is presented repeatedly without the negative
associated stimulus (unconditioned stimulus), resulting in extinc-
tion of the nocebo effect over a number of trials.4,44,57 In a clinical
setting, this would translate to presenting contextual cues of the
treatment environment without any associated negative effects.
However, it seems that, once established, nocebo effects are
difficult to reverse.19,20,32 It is suggested that the mediating effect
of anxiety and autonomic arousal may inhibit the learning of new
associations.19
Another, less studied mechanism that may reverse nocebo
effects is counterconditioning, in which a conditioned contextual
cue is still present, but is now associated with a positive
unconditioned stimulus.62,96,117 For instance, a study7 showed
that nocebo effects of itch can be minimized and even reversed
by means of counterconditioning in combination with verbal
suggestions. In the first part of the study, negative expectations
on itch were induced in healthy adults by means of verbal
suggestions and a conditioning procedure. In the second part,
positive expectations were induced again by means of verbal
suggestions in combination with a conditioning procedure, or an
extinction procedure was applied. Turning previously negative
learned associations into positive associations not only signifi-
cantly reduced nocebo itch but actually completely reversed the
effects, indicating a placebo effect. Finally, a study by Benedetti
et al.15 showed that verbal suggestions of analgesia and
hyperalgesia on induced ischemic arm pain alone can completely
counteract the effects of a conditioning procedure in healthy
adults. The same study also showed that verbal suggestions on
motor improvement or worsening also counteracted a condition-
ing procedure in patients with Parkinson disease. These studies
indicate that, while extinction learning may not be sufficient to
totally reverse acquired nocebo effects, counterconditioning and
verbal suggestions may be powerful strategies to minimize and
even reverse the nocebo effect in clinical populations.
6. Conclusion
This narrative review provides an overview of possible factors that
contribute to the development of the nocebo effect in pain and
related conditions and could therefore result in increased side
effects, reduced treatment efficacy, and reduced quality of life.
However, various opportunities exist that could prevent or
minimize the occurrence of the nocebo effect, such as managing
patient expectations by offering enhanced treatment and side
effect information, optimizing communication style of health care
providers and their relationship with patients, and providing
psychoeducation on coping skills to manage patient expect-
ations. Strategies may also be applied to extinguish nocebo
effects once they are established, such as counterconditioning.
Although these strategies may be used to alter the nocebo effect,
more research is needed on its underlyingmechanisms to identify
possible factors that contribute to the susceptibility and develop
more therapeutic approaches that can minimize nocebo effects
in clinical settings. Furthermore, although there exists
considerable knowledge of underlying mechanisms of nocebo
learning, more research is needed on the application of this
knowledge in various clinical (pain) populations.
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